Caricamento...
Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children
Rituximab, a chimeric anti-CD20 monoclonal antibody originally licensed for lymphoma, is emerging as a novel steroid-sparing agent for idiopathic nephrotic syndrome in children. The potential use of anti-CD20 monoclonal antibodies in idiopathic nephrotic syndrome has contributed to shifting the view...
Salvato in:
| Pubblicato in: | Clin J Am Soc Nephrol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Nephrology
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4822672/ https://ncbi.nlm.nih.gov/pubmed/26585985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08500815 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|